Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Relacorilant · Lifyorli, CORT-125134

Small molecule · Antagonist of glucocorticoid receptor (NR3C1) · developed by Corcept Therap

Approved FDA, Mar 2026

CORT Developer

8 Registered trials

What is Relacorilant?

Relacorilant is an orally available reversible glucocorticoid receptor antagonist. It blocks GR activity to prevent immunosuppression from endogenous cortisol and inhibit proliferation of GR-overexpressing cancer cells.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Lifyorli, CORT-125134
Drug type: Small molecule
Targets: glucocorticoid receptor (NR3C1)
Mechanism: Antagonist of glucocorticoid receptor (NR3C1)
Pathways: immune activation, apoptosis
Therapy area: Endocrine, Oncology
Developer: Corcept Therap (CORT)
FDA status: Approved as Lifyorli (March 25, 2026), NDA220641 · FDA label
UNII: 2158753C7E

✅ FDA-approved uses

Platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

From the indications section of the FDA label (version of Mar 26, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05257408	Phase 3	Ovarian Neoplasm	Active not recruiting	CORT
NCT04308590	Phase 3	Hypercortisolism	Completed	CORT
NCT04329949	Phase 3	Metastatic Pancreatic Ductal Adenocarcinoma	Terminated	CORT
NCT06906341	Phase 2	Ovarian Cancer	Recruiting	CORT
NCT06094738	Phase 1	Healthy	Completed	CORT
NCT03512548	Phase 1	Healthy	Completed	CORT
NCT06094790	Phase 1	Healthy	Completed	CORT
NCT06094712	Phase 1	Healthy	Completed	CORT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrial CancerFallopian Tube CancerFallopian Tube NeoplasmsOvarian CancerOvarian NeoplasmPeritoneal NeoplasmsHealthyHypercortisolismMetastatic Pancreatic Ductal Adenocarcinoma

Other drugs acting on NR3C1

Beclomethasone Dipropionate FDA approved Budesonide FDA approved IDP-118 FDA approved Infacort FDA approved Methylprednisolone FDA approved Mifepristone FDA approved Mometasone FDA approved Mometasone Furoate FDA approved Chronocort Phase 3 Exicorilant Phase 1/2 Miricorilant Phase 2 ORIC-101 Phase 1

More from Corcept Therap

CORT125236 Phase 1 CORT125329 Phase 1 Dazucorilant Phase 2 Exicorilant Phase 1/2 Miricorilant Phase 2 Nenocorilant Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CORT page.

Follow CORT, the company behind Relacorilant

See CORT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CORT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z